The research company Peptonic Medical's reconstruction plan has gained legal force following a decision by Uppsala tingsrätt on November 28, which means that the corporate reconstruction is now concluded. The company will therefore move forward with implementing the measures included in the plan. This is stated in a press release. The measures include, among other things, a directed share issue by way of set-off and a rights issue to existing shareholders of approximately SEK 15 million, of which at least SEK 10 million is to be covered by subscription undertakings and underwriting commitments. The share issues are to be carried out within two months and are conditional on the necessary approvals as well as an exemption from the mandatory bid obligation.